Annovis Bio Inc reports results for the quarter ended September 30 - Earnings Summary

Annovis Bio

09/11/2024 12:26

* Annovis Bio Inc  ANVS.N  reported a quarterly adjusted
loss
of 97 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-1.63.  The mean expectation of six analysts
for the quarter was for a loss of 53 cents per share. Wall
Street expected results to range from -65 cents to -38 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Annovis Bio Inc's reported EPS for the quarter was a loss
of 97
cents​.
    * The company reported a quarterly loss of $12.64 million.
    * Annovis Bio Inc shares had risen by 6.8% this quarter and
lost 54.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 49.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Annovis Bio Inc
is $26.00 
This summary was machine generated from LSEG data November 9 at
12:25 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.53          -0.97          Missed
 Jun. 30 2024      -0.63          -0.32          Beat
 Mar. 31 2024      -0.80          -0.10          Beat
 Dec. 31 2023      -1.30          -2.24          Missed